MicroPort Scientific (HKG:0853) expects to record a net loss of about $275 million for 2024, a decrease of 58% compared with the same period a year earlier, according to a Friday filing with the Hong Kong bourse.
The company attributed the narrowing of loss to the 10% revenue growth despite industry challenges, with overseas business increasing 80% year-on-year. Cost optimization improved efficiency, reducing the operating expense ratio by 28% points year-on-year. Additionally, the successful divestment of non-core businesses contributed positively to the overall financial performance.
The manufacturer and sellers of medical products plan to publish their annual results by the end of March.
The company's shares were down over 5% at the close of trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。